Malta - English - Medicines Authority

fresenius medical care deutschland gmbh d-61346 bad homburg, germany - calcium, glucose - solution for peritoneal dialysis - calcium 1.25 mmol/l glucose 1.5 % (w/v) - blood substitutes and perfusion solutions

Malta - English - Medicines Authority

fresenius medical care deutschland gmbh d-61346 bad homburg, germany - calcium, glucose - solution for peritoneal dialysis - calcium 1.25 mmol/l glucose 2.3 % (w/v) - blood substitutes and perfusion solutions

Malta - English - Medicines Authority

fresenius medical care deutschland gmbh d-61346 bad homburg, germany - calcium, glucose - solution for peritoneal dialysis - calcium 1.25 mmol/l glucose 4.25 % (w/v) - blood substitutes and perfusion solutions

Malta - English - Medicines Authority

fresenius medical care deutschland gmbh d-61346 bad homburg, germany - calcium, glucose - solution for peritoneal dialysis - calcium 1.75 mmol/l glucose 1.5 % (w/v) - blood substitutes and perfusion solutions

Malta - English - Medicines Authority

fresenius medical care deutschland gmbh d-61346 bad homburg, germany - calcium, glucose - solution for peritoneal dialysis - calcium 1.75 mmol/l glucose 2.3 % (w/v) - blood substitutes and perfusion solutions

Malta - English - Medicines Authority

fresenius medical care deutschland gmbh d-61346 bad homburg, germany - calcium, glucose - solution for peritoneal dialysis - calcium 1.75 mmol/l glucose 4.25 % (w/v) - blood substitutes and perfusion solutions

European Union - English - EMA (European Medicines Agency)

mylan s.a.s. - lopinavir/ritonavir - hiv infections - antivirals for systemic use, - lopinavir/ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv-1) infected adults, adolescents and children above the age of 2 years.the choice of lopinavir/ritonavir to treat protease inhibitor experienced hiv-1 infected patients should be based on individual viral resistance testing and treatment history of patients.

European Union - English - EMA (European Medicines Agency)

zentiva k.s. - efavirenz, emtricitabine, tenofovir disoproxil, phosphate - hiv infections - antivirals for systemic use, - efavirenz/emtricitabine/tenofovir disoproxil zentiva is a fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil. it is indicated for the treatment of human immunodeficiency virus-1 (hiv-1) infection in adults aged 18 years and over with virologic suppression to hiv-1 rna levels of < 50 copies/ml on their current combination antiretroviral therapy for more than three months. patients must not have experienced virological failure on any prior antiretroviral therapy and must be known not to have harboured virus strains with mutations conferring significant resistance to any of the three components contained in efavirenz/emtricitabine/tenofovir disoproxil zentiva prior to initiation of their first antiretroviral treatment regimen., the demonstration of the benefit of the combination efavirenz/emtricitabine/tenofovir disoproxil is primarily based on 48-week data from a clinical study in which patients with stable virologic suppression on a combination antiretroviral therapy changed to efavir

European Union - English - EMA (European Medicines Agency)

ipsen pharma - mecasermin - laron syndrome - pituitary and hypothalamic hormones and analogues - for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like-growth-factor-1 deficiency (primary igfd).severe primary igfd is defined by:height standard deviation score ≤ -3.0 and;basal insulin-like growth factor-1 (igf-1) levels below the 2.5th percentile for age and gender and;growth hormone (gh) sufficiency;exclusion of secondary forms of igf-1 deficiency, such as malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory steroids.severe primary igfd includes patients with mutations in the gh receptor (ghr), post-ghr signalling pathway, and igf-1 gene defects; they are not gh deficient, and therefore, they cannot be expected to respond adequately to exogenous gh treatment. it is recommended to confirm the diagnosis by conducting an igf-1 generation test.